Duloxetine for depression and the incidence of hepatic events in adults

Journal of Clinical Psychopharmacology

Volumn 31, Issue 4, 2011, Pages 517-522

  Xue, Fei ^a   Strombom, Indiana ^b   Turnbull, Bruce ^c   Zhu, Shao ^c   Seeger, John D ^c,d  

^a AMGEN INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Ingenix i3 Drug Safety   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

duloxetine; hepatic events; pharmacoepidemiology; safety

Indexed keywords

DULOXETINE; LIVER ENZYME; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DRUG FATALITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; COHORT STUDIES; DEPRESSION; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THIOPHENES; YOUNG ADULT;

EID: 79960607735     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822347d9     Document Type: Article

References (14)

1. DeSanty KP, Amabile CM. Antidepressant-induced liver injury. Ann Pharmacother. 2007;41:1201-1211. (Pubitemid 47122557)
2. Ostapowicz G, Fontana RJ, SchiLdt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-954. (Pubitemid 35440240)
3. Bleibel W, Kim S, D'Silva K, et al. Drug-induced liver injury: review article. Dig Dis Sci. 2007;52:2463-2471. (Pubitemid 47373878)
4. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272-276.
5. Danan G, Benichou C. Causality assessment of adverse reactions to drugsVI. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323-1330. (Pubitemid 23333873)
6. Lee WM. Acute liver failure in the United States. Semin Liver Dis. 2003;23:217-226. (Pubitemid 37052447)
7. Strombom I, Wernicke JF, Seeger J, et al. Hepatic effects of duloxetineVIII: analysis of hepatic events using external data sources. Curr Drug Saf. 2008;3:154-162.
8. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333. (Pubitemid 29383480)
9. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
10. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1988;70:41-55.
11. Rothman KJ, Ray W. Should cases with a 'known' cause of their disease be excluded from study? [commentary]. Pharmacoepidemiol Drug Saf. 2002;11:11-14. (Pubitemid 34269591)
12. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15:291-303. (Pubitemid 43797117)
13. US Food and Drug Administration. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation Reference. 2007. Available at: http://www.fda.gov/Cder/guidance/7507dft.htm. Accessed May 30, 2008.
14. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003;163:728-734. (Pubitemid 36343367)